Enosi Life Sciences
Expanding Visionary Autoimmune & Cancer Research and Combining Multiple Scientific Solutions to Achieve a Single Goal: Improving Lives
More than 30% of patients treated with life-changing therapeutics do not respond, or relapse, even with continued treatment. Enosi Life Sciences’ founders are building upon their Lasker Award-winning research to address and conquer these issues.
Enosi’s founders are developing breakthrough biologics that will bring drugs with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. This will be the next generation of autoimmune, cancer, and acute inflammation therapies that induce disease regression and prevent relapse while reduci...
- Security Type
- Common Stock
- Min Investment
- Offering Date
- July 19, 2021
- Security Price
Use of Proceeds
$2.5M to be raised in current offerings for us to make significant progress (timeframe 1-2y).
A total of $5M will carry the company through its first laboratory proof of concept studies (2-3y), which could make Enosi a candidate for acquisition by a larger biotech company.
A total of $12.5M will be needed to power Enosi to its first clinical trial.
Over 25 years of pharmaceutical research and management expertise.
Mr. Jeff Huitt, CEO
Jeff has more than 20 years' experience driving the financial function at start-ups and public companies.
Dr. Michael Shepard, CEO and Co-Founder
First FDA-approved monoclonal antibody therapy targeting breast cancer and other solid tumors...Herceptin.
- Investments at or above $5,000 are invited to a 30-minute Zoom to be scheduled with the Founders at the close of the campaign. This discussion will focus on an open Q&A and discussion on the science behind Enosi.
No reports have been submittedBecome a Reporter